Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 526


Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?

Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, Djakovic N, Buse S, Pahernik S, Hohenfellner M.

BJU Int. 2009 Apr;103(7):877-82. doi: 10.1111/j.1464-410X.2008.08149.x. Epub 2008 Oct 24.


Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.

van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, van Oort IM, Hulsbergen-van de Kaa CA, van Leenders GJ, Bangma CH, Witjes JA.

BJU Int. 2009 Aug;104(3):321-5. doi: 10.1111/j.1464-410X.2009.08404.x. Epub 2009 Feb 11.


Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.

King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr.

Urology. 2007 May;69(5):921-6.


Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients.

Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M.

World J Urol. 2009 Oct;27(5):637-42. doi: 10.1007/s00345-009-0414-0. Epub 2009 Apr 26.


Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.

Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F.

Int J Urol. 2009 Aug;16(8):676-81. doi: 10.1111/j.1442-2042.2009.02330.x. Epub 2009 Jul 8.


Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?

Pfitzenmaier J, Pahernik S, Tremmel T, Haferkamp A, Buse S, Hohenfellner M.

BJU Int. 2008 Nov;102(10):1413-8. doi: 10.1111/j.1464-410X.2008.07791.x. Epub 2008 Jun 4.


Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG.

J Clin Oncol. 2004 Feb 1;22(3):439-45. Epub 2003 Dec 22.


Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.


Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.

Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK.

J Clin Oncol. 2004 Feb 1;22(3):446-53. Epub 2003 Dec 22.


Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.

Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML.

Cancer. 2006 Aug 1;107(3):521-9.


The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy.

Hayashi N, Urashima M, Kuruma H, Arai Y, Kuwao S, Iwamura M, Egawa S.

BJU Int. 2008 Jan;101(2):175-80. Epub 2007 Sep 10.


Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.

Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1302-8. doi: 10.1016/j.ijrobp.2007.11.073. Epub 2008 Feb 11.


Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.

Palma D, Pickles T, Tyldesley S; Prostate Cohort Outcomes Initiative.

BJU Int. 2007 Aug;100(2):315-9.


Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.

J Urol. 2007 Jan;177(1):102-6; discussion 106.


Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.

Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML.

BJU Int. 2008 Feb;101(3):299-304. Epub 2007 Oct 8.


The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome.

Pierorazio P, Desai M, McCann T, Benson M, McKiernan J.

BJU Int. 2009 Jan;103(1):38-42. doi: 10.1111/j.1464-410X.2008.07952.x. Epub 2008 Sep 3.


[Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age].

Wang Y, Zhou Z, Tian Y, Shao Q, Chen S, Hong BF, Zhang XH, Ren XH, Sun WX, Wang ZW, Na YQ.

Zhonghua Yi Xue Za Zhi. 2009 Jun 23;89(24):1681-3. Chinese.


Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk